SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers
SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers
Hassan Serrier, Nozomu Yanaihara, I Bruchim, J. R. Kroep et al.
Journal
Therapeutic Advances in Medical Oncology
Topics
Ovarian cancer diagnosis and treatment
article
SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers
Hassan Serrier, Nozomu Yanaihara, I Bruchim, J. R. Kroep, A. Clamp, Gabriella Maria Parma, Anne-Sophie Belmont, Susan Carroll, Alexandra L. Dima, Claire Chator, Sylvie Chabaud, Julien Peron, Frederic Fiteni, Benoit You, David Cibula, Alexandra Leary, Gwenaël Ferron
article en
Abstract
No abstract available for this paper.
Publication Tag
Therapeutic Advances in Medical OncologyVol. 17
Institutions
Jikei University School of Medicine (JP), Universitat Autònoma de Barcelona (ES), Technion – Israel Institute of Technology (IL), Charles University (CZ), Leiden University Medical Center (NL), Hillel Yaffe Medical Center (IL), Institut Gustave Roussy (FR), Hospices Civils de Lyon (FR), Hôpital Lyon Sud (FR), Centro de Investigación Biomédica en Red (ES), Centre de Recherche en Cancérologie de Lyon (FR), Institut Claudius Regaud (FR), Parc Sanitari Sant Joan de Déu (ES), The Christie Hospital (GB), Arcagy Gineco (FR), Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES), Centro de Investigación Biomédica en Red de Cáncer (ES), General University Hospital in Prague (CZ), Oldham Council (GB), European Institute of Oncology (IT), Université de Nîmes (FR), HCL Technologies (India) (IN)